Associate Director, Clinical Science

Braveheart Bio•San Francisco, CA

About The Position

The Associate Director, Clinical Science will serve as a key scientific contributor within Braveheart Bio’s Clinical Development organization, partnering closely with Clinical Development Medical Directors to shape and execute the clinical and translational science strategy for BHB-1893 across obstructive and non-obstructive hypertrophic cardiomyopathy. The role will contribute to preparing BHB-1893 for global Phase 3 execution and regulatory submissions. The position provides scientific leadership for protocol design and endpoint strategy, clinical data review and quality, independent analysis of clinical, biomarker, and exploratory endpoint data, and the scientific content of clinical study reports, publications, and regulatory documents. Working cross-functionally with Biometrics, Clinical Pharmacology, Data Management, and Clinical Operations, the Associate Director will translate complex datasets into scientific insights that inform program decisions, drawing on sarcomere biology and disease-specific pharmacodynamic considerations. The Associate Director will also serve as a clinical science point of contact for Braveheart’s global co-development partnership, supporting clinical data review, cleaning, and reconciliation and promoting consistent scientific interpretation across global development programs. The role will help represent BHB-1893’s science to key opinion leaders, advisory boards, and the broader cardiovascular scientific community.

Requirements

PhD or equivalent research doctorate; other advanced degrees, such as a PharmD or an MS with substantial relevant experience, will be considered.
At least 6 years of experience in clinical development and/or translational research.
Demonstrated experience conducting hands-on review and quality control of clinical data listings.
Experience collaborating with co-development partners, CROs, or other external organizations on clinical data review, cleaning, and reconciliation; global Phase 3 trials through database lock are ideal.
Strong independent data analysis skills, including the ability to identify patterns, anomalies, and scientific signals in complex clinical datasets.
Working knowledge of cardiovascular disease biology, ideally including sarcomere biology and hypertrophic cardiomyopathy.
Experience authoring or contributing to clinical study protocols, clinical study reports, and regulatory documents such as NDA/MAA submissions.
Strong interpersonal and communication skills to bridge scientific and business participants, negotiate timelines, and collaborate internationally.
Strong written and verbal communication skills and a collaborative, team-oriented approach.
Ability to thrive in a fast-paced, dynamic environment and remain comfortable with change and ambiguity.
Flexible, proactive, hands-on mindset with a roll-up-your-sleeves, can-do attitude.

Nice To Haves

Programming experience in R, Python, or SAS sufficient to analyze clinical datasets.
Track record of developing novel analytic approaches to complex biomarker or clinical trial data.
Experience engaging with key opinion leaders or scientific advisory boards, or presenting at cardiovascular conferences such as ESC, AHA, or HFSA.
Fluency in Mandarin.

Responsibilities

Partner with Clinical Development leads to shape the translational and clinical science strategy for BHB-1893 across obstructive and non-obstructive hypertrophic cardiomyopathy.
Provide scientific input into protocol design and endpoint selection, drawing on sarcomere biology and disease-specific pharmacodynamic considerations.
Lead clinical and scientific review of clinical data listings and identify and resolve data anomalies in partnership with Biometrics.
Serve as a clinical science point of contact with Braveheart’s global co-development partner, supporting clinical data review, cleaning, and reconciliation and resolving discrepancies across global Phase 3 programs.
Independently analyze clinical, biomarker, and exploratory endpoint data to generate scientific insights that inform program strategy.
Develop exploratory analyses with Biometrics and Clinical Pharmacology to interrogate complex datasets.
Author and review clinical study reports, investigator brochures, abstracts and publications, and scientific components of regulatory submissions, including NDA/MAA submissions.
Represent the science of BHB-1893 with key opinion leaders, at scientific conferences, and in advisory board settings.